- Home
- RGNX vs IMAB Comparison
RGNX vs IMAB Comparison
Compare RGNX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- IMAB
- Stock Information
- Founded
- RGNX 2008
- IMAB 2014
- Country
- RGNX United States
- IMAB United States
- Employees
- RGNX N/A
- IMAB N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- IMAB Health Care
- Exchange
- RGNX Nasdaq
- IMAB Nasdaq
- Market Cap
- RGNX 445.5M
- IMAB 384.6M
- IPO Year
- RGNX 2015
- IMAB 2020
- Fundamental
- Price
- RGNX $8.82
- IMAB $4.50
- Analyst Decision
- RGNX Strong Buy
- IMAB Strong Buy
- Analyst Count
- RGNX 8
- IMAB 4
- Target Price
- RGNX $28.50
- IMAB $6.75
- AVG Volume (30 Days)
- RGNX 687.5K
- IMAB 4.8M
- Earning Date
- RGNX 08-07-2025
- IMAB 08-20-2025
- Dividend Yield
- RGNX N/A
- IMAB N/A
- EPS Growth
- RGNX N/A
- IMAB N/A
- EPS
- RGNX N/A
- IMAB N/A
- Revenue
- RGNX $155,782,000.00
- IMAB N/A
- Revenue This Year
- RGNX $327.08
- IMAB N/A
- Revenue Next Year
- RGNX N/A
- IMAB N/A
- P/E Ratio
- RGNX N/A
- IMAB N/A
- Revenue Growth
- RGNX 74.95
- IMAB N/A
- 52 Week Low
- RGNX $5.04
- IMAB $0.60
- 52 Week High
- RGNX $13.48
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- RGNX 53.29
- IMAB 57.46
- Support Level
- RGNX $7.83
- IMAB $4.13
- Resistance Level
- RGNX $9.24
- IMAB $5.64
- Average True Range (ATR)
- RGNX 0.51
- IMAB 0.64
- MACD
- RGNX 0.08
- IMAB 0.01
- Stochastic Oscillator
- RGNX 77.37
- IMAB 46.15
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).